Clinical trials: FDG-PET
Major Depressive Disorder
Changes in Cerebral Glucose Metabolism After Electroconvulsive Therapy (ECT)
There exist already a few studies that have measured changes of brain metabolism pre and post Electroconvulsive Therapy (ECT) by Positron emission tomography (PET) but these were all performed in a small number of patients and…
- Trial name
- NCT01514435
- Testing
- Electroconvulsive therapy, 18-Fluoro-desoxy-glucose positron emission tomography
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- Medical University of Graz
Ovarian Cancer, Primary Peritoneal Cancer
Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)
This study will characterize FDG-PET (18F-Fluorodeoxyglucose-Positron Emission Tomography) as an early response marker in recurrent, platinum-sensitive ovarian cancer treated with platinum-based therapy.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00959582
- Testing
- Comparator: 18-F-FDG PET/CT and Volumetric CT
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer s Disease
Terazosin And Metabolic Engagement in Alzheimer's Disease
The TAME-AD trial will be a randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the metabolic target engagement of terazosin for the treatment of Alzheimer's disease.
- Trial name
- TAME-AD (NCT07796308)
- Testing
- Terazosin (Hytrin)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Qiang Zhang
Abdominal Aortic Aneurysm
Endoprosthesis Treatment Effects on Human Abdominal Aorta Aneurysms (AAA) Metabolic Activity
The purpose of this study is to determine whether Positron Emission Tomography imaging can help to predict the evolutivity of AAA treated with endovascular prosthesis.
- Trial name
- AAAendo (NCT01253252)
- Testing
- [18F] Fluorodeoxyglucose PET Scan Imaging, CT scan, Blood sampling for biological investigations
- Where
- 7 sites in France
- Volunteers
- 45 people
- Sponsor
- Central Hospital, Nancy, France
Colon Cancer
18F-FDG PET/CT and Molecular Tumor Characterisation for Staging and Follow-up of Colon Cancer
The investigators are investigating the usefulness of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography (18F-FDG PET/CT) for staging and follow-up of colon cancer.
- Trial name
- COLOPET1 (NCT01636674)
- Testing
- 18F-fluordeoxyglucose positron emission tomography/ computed tomography
- Volunteers
- 66 people
- Sponsor
- Naestved Hospital
Cardiac Sarcoidosis
Feasibility and Accuracy of Hybrid Magnetic Resonance and Positron Emission Tomography With 18F-Fluorodeoxyglucose in Diagnosing Cardiac Sarcoidosis
The purpose and objectives of the study is to establish the feasibility of the simultaneous PET/MR in patients with cardiac sarcoidosis, determine relationships between various imaging biomarkers like extracellular volume (ECV)…
- Trial name
- NCT03923049
- Testing
- hybrid PET/MRI
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham
Atherosclerosis
Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques.
- Trial name
- NCT00926055
- Testing
- Ezetrol (Ezetimibe), Vytorin (Ezetimibe + Simvastatin)
- Where
- South Korea
- Volunteers
- healthy volunteers welcome
- Sponsor
- Korea University
Atherosclerotic Vascular Disease
Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque (MK-0000-081 AM3)(COMPLETED)
The purpose of this study is to evaluate the utility of 18Fluorine Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET) as a tool to quantify atherosclerotic plaque.
- Trial name
- NCT00703261
- Testing
- atorvastatin
- Volunteers
- 83 people
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of the Head and Neck
Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection
Early detection of viable residual tumor or early neoplastic recurrence represents a real challenge in monitoring patients treated with concomitant chemoradiotherapy squamous cell carcinoma of the upper aerodigestive tract.
- Trial name
- TEPVAD (NCT02510872)
- Testing
- 18F-FDG PET combined with CT with iodinated contrast injection, 18F-FDG PET combined with CT without injection
- Where
- France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Caen
Prostate Cancer (Diagnosis), Prostate-specific Membrane Antigen
Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer
The purpose of this study is to analyze heterogeneity of prostate cancer（PCa）based on the head-to-head imaging of prostate-specific membrane antigen (PSMA) and fluorodeoxyglucose (FDG) positron emission tomography computed…
- Conditions
- Prostate Cancer (Diagnosis), Prostate-specific Membrane Antigen, Positron Emission Tomography (PET)
- Trial name
- NCT06919159
- Testing
- PSMA PET/CT scan, FDG-PET
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Jiequn Yu
Tuberculosis, Pulmonary
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in…
- Trial name
- StatinTB (NCT04147286)
- Testing
- Atorvastatin 40mg
- Where
- South Africa
- Volunteers
- 220 people
- Sponsor
- University of Cape Town
Tumors
18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology
This clinical trial is being conducted to study the use of a radioactive glucose tracer as an imaging test [Positron Emission Tomography (PET)scan] in adults who have or are suspected of having cancer and in another group of…
- Trial name
- NCT01180751
- Testing
- [18F]-Fluorodeoxyglucose
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- University of Manitoba
HER2 Positive Gastric Cancer
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System
The positive rate of HER2 in Chinese patients with gastric cancer is about 12-13%. HER2 positive gastric cancer has strong invasion, high metastasis rate and poor prognosis.
- Trial name
- NCT05165602
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University
Carcinoma, Renal Cell
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
The purpose of this study is to learn if PET scanning can predict the degree of tumor shrinkage with the study drug RAD001 in subjects who have advanced renal cancer.
- Trial name
- NCT00529802
- Testing
- RAD001
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Chicago
Head and Neck Cancer
RAdiotherapy With FDG-PET Guided Dose-PAINTing for Primary Head and Neck
Dose-painting may increase the chance of cure at minimised radiation-induced toxicity in volumetric-arc radiotherapy (VMAT) for head and neck cancer.
- Trial name
- RADPAINT-2 (NCT04910308)
- Testing
- FDG-PET guided dose painting
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- Oslo University Hospital
Cervical Cancer
Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Cervical Heterogenity Imaging Study
Rationale: Diagnostic procedures, such as positron emission tomography (PET) using fluorodeoxyglucose (FDG), may help determine response to standard cancer therapy in patients with cervical cancer The purpose of this study is to…
- Trial name
- NCT00907140
- Testing
- Positron Emission Tomography
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy
At present, it is recommended to continue immunotherapy until progression or unacceptable toxicity. However, only a minority of patients benefits from a durable response and most see the disease progress despite several months of…
- Trial name
- TRAILOCLORI01 (NCT05111197)
- Testing
- SRT, Immunotherapy
- Where
- 5 sites in France
- Volunteers
- 112 people
- Sponsor
- Institut Cancerologie de l'Ouest
HIV
Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption
Background: Human immunodeficiency virus (HIV) infects CD4 T cells. There is no cure for HIV. People with HIV need to take daily medications called antiretroviral therapy (ART) to control their infection.
- Trial name
- NCT05419024
- Testing
- Acute Treatment Interruption
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Glioma, Astrocytoma
Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas
As a part of molecular imaging, many PET tracers have been investigated in this regard. Those include 18F-FDG being glucose analogue, 18F-FLT representing nucleoside metabolism, and 18F-FDOPA, 18F-FET, 11C-MET as amino acids…
- Conditions
- Glioma, Astrocytoma, Anaplastic Astrocytoma, Oligodendroglioma
- Trial name
- NCT06241391
- Testing
- PSMA PET-CT
- Where
- India
- Volunteers
- 35 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Carcinoma, Non-Small-Cell Lung
Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer
Objective: L-[3-18F]-α-methyltyrosine (FMT) is an amino-acid tracer for PET. We evaluated the diagnostic usefulness of 18F-FMT PET in non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT00464282
- Sponsor
- Gunma University